IVIVC of Octreotide in PLGA-Glucose Microsphere Formulation, Sandostatin ® LAR
In this study, in vitro release of octreotide from SLD was investigated using the release test media each containing 0.02% or 0.5% surfactant and having different pH values of 7.4 and 5.5. In vivo pharmacokinetic profiles of SLD were determined by LC-MS/MS analysis of the systemic blood concentration of octreotide after the SLD injection to rodents. In IVIVC analysis, the Weibull model was adopted as a drug release model for biodegradable microsphere formulation. The IVIVC analyses revealed the in vitro release test condition of SLD with the highest IVIV correlation coefficient. By applying the in vitro release data to the...
Source: AAPS PharmSciTech - September 19, 2022 Category: Drugs & Pharmacology Authors: Jin-Sook Song So-Yeon Kim Jae-Hyun Nam Jaehwi Lee Sang-Yong Song Hasoo Seong Source Type: research

IVIVC of Octreotide in PLGA-Glucose Microsphere Formulation, Sandostatin ® LAR
In this study, in vitro release of octreotide from SLD was investigated using the release test media each containing 0.02% or 0.5% surfactant and having different pH values of 7.4 and 5.5. In vivo pharmacokinetic profiles of SLD were determined by LC-MS/MS analysis of the systemic blood concentration of octreotide after the SLD injection to rodents. In IVIVC analysis, the Weibull model was adopted as a drug release model for biodegradable microsphere formulation. The IVIVC analyses revealed the in vitro release test condition of SLD with the highest IVIV correlation coefficient. By applying the in vitro release data to the...
Source: AAPS PharmSciTech - September 19, 2022 Category: Drugs & Pharmacology Authors: Jin-Sook Song So-Yeon Kim Jae-Hyun Nam Jaehwi Lee Sang-Yong Song Hasoo Seong Source Type: research

IVIVC of Octreotide in PLGA-Glucose Microsphere Formulation, Sandostatin ® LAR
In this study, in vitro release of octreotide from SLD was investigated using the release test media each containing 0.02% or 0.5% surfactant and having different pH values of 7.4 and 5.5. In vivo pharmacokinetic profiles of SLD were determined by LC-MS/MS analysis of the systemic blood concentration of octreotide after the SLD injection to rodents. In IVIVC analysis, the Weibull model was adopted as a drug release model for biodegradable microsphere formulation. The IVIVC analyses revealed the in vitro release test condition of SLD with the highest IVIV correlation coefficient. By applying the in vitro release data to the...
Source: AAPS PharmSciTech - September 19, 2022 Category: Drugs & Pharmacology Authors: Jin-Sook Song So-Yeon Kim Jae-Hyun Nam Jaehwi Lee Sang-Yong Song Hasoo Seong Source Type: research

Medical management of pancreatic neuroendocrine tumors in patients with MEN 1: case report
ConclusionsNow she is well after four years of treatment with Sandostatin LAR. (Source: Journal of Diabetes and Metabolic Disorders)
Source: Journal of Diabetes and Metabolic Disorders - June 29, 2022 Category: Endocrinology Source Type: research

EE332 A Budget Impact Model for Terlipressin in Treating Bleeding Oesophageal Varices Patients in the Philippines
The objective of our analysis was to quantify the budget impact of using terlipressin for treating BOV patients from the Philippines health system perspective. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: E Yasay, A Lai, AD Irmawan, MT Panlilio, J Ong, E Wu, J Kim, B Wang Source Type: research

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy
CONCLUSIONS: In patients with disease control after PRRT, subsequent SSA treatment appeared not to be associated with better PFS or OS. Whether to continue SSA administration upon progression after PRRT requires evaluation in a prospective, randomised, controlled multicentre study with a relatively homogeneous sample.PMID:35503379 | DOI:10.1007/s00259-022-05792-y (Source: Molecular Medicine)
Source: Molecular Medicine - May 3, 2022 Category: Molecular Biology Authors: Aleksandra Sygu ła Aleksandra Ledwon Kornelia Hasse-Lazar Beata Jurecka-Lubieniecka Barbara Michalik Ewa Paliczka-Cie ślik Marcin Zeman Ewa Chmielik Joanna Sczasny Barbara Jarzab Daria Handkiewicz-Junak Source Type: research

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy
ConclusionsIn patients with disease control after PRRT, subsequent SSA treatment appeared not to be associated with better PFS or OS. Whether to continue SSA administration upon progression after PRRT requires evaluation in a prospective, randomised, controlled multicentre study with a relatively homogeneous sample. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 3, 2022 Category: Nuclear Medicine Source Type: research

The palliative management of non-islet cell tumour hypoglycaemia with glucocorticoids and somatostatin analogues in an unresectable hepatocellular carcinoma
Ann R Coll Surg Engl. 2022 Feb 8. doi: 10.1308/rcsann.2021.0269. Online ahead of print.ABSTRACTNon-islet cell tumour hypoglycaemia (NICTH) results from paraneoplastic insulin-like growth factor-II (IGF-II) secretion and its potent insulin-like effect. It causes recurrent, often severe, hypoglycaemic episodes, which is detrimental to quality of life. There is limited evidence regarding best supportive care in unresectable tumours. A 76-year-old woman presented with hypoglycaemic collapse. A new diagnosis of unresectable hepatocellular carcinoma (HCC) was made. The IGF-II:IGF-I ratio was 11.0, which confirmed NICTH. The octr...
Source: Annals of the Royal College of Surgeons of England - February 8, 2022 Category: Surgery Authors: A S North R G Thakkar R A James J S Hammond Source Type: research

The palliative management of non-islet cell tumour hypoglycaemia with glucocorticoids and somatostatin analogues in an unresectable hepatocellular carcinoma
Ann R Coll Surg Engl. 2022 Feb 8. doi: 10.1308/rcsann.2021.0269. Online ahead of print.ABSTRACTNon-islet cell tumour hypoglycaemia (NICTH) results from paraneoplastic insulin-like growth factor-II (IGF-II) secretion and its potent insulin-like effect. It causes recurrent, often severe, hypoglycaemic episodes, which is detrimental to quality of life. There is limited evidence regarding best supportive care in unresectable tumours. A 76-year-old woman presented with hypoglycaemic collapse. A new diagnosis of unresectable hepatocellular carcinoma (HCC) was made. The IGF-II:IGF-I ratio was 11.0, which confirmed NICTH. The octr...
Source: Annals of the Royal College of Surgeons of England - February 8, 2022 Category: Surgery Authors: A S North R G Thakkar R A James J S Hammond Source Type: research

Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors
CONCLUSIONS: Overall, there was no difference in PFS between octreotide LAR and somatuline depot for pts with well-differentiated, metastatic GEP-NETs. A prospective study is worth designing selecting for G.PMID:35078191 | DOI:10.1159/000519605 (Source: Oncology)
Source: Oncology - January 25, 2022 Category: Cancer & Oncology Authors: Mohammed B Allaw Jeffrey M Switchenko Lana Khalil Christina Wu Olatunji B Alese Mehmet Akce Amber Draper Aaron T Jones Bassel El-Rayes Walid Shaib Source Type: research

Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors
Conclusions: Overall, there was no difference in PFS between octreotide LAR and somatuline depot for pts with well-differentiated, metastatic GEP-NETs. A prospective study is worth designing selecting for G.Oncology (Source: Oncology)
Source: Oncology - January 25, 2022 Category: Cancer & Oncology Source Type: research

Pancreatic neuroendocrine tumor with ectopic adrenocorticotropic hormone syndrome: a case report and 5-year follow-up
Endocr J. 2021 Oct 9. doi: 10.1507/endocrj.EJ21-0297. Online ahead of print.ABSTRACTPancreatic neuroendocrine tumors (P-NETs) secreting ectopic adrenocorticotropic hormones (ACTH) are rare and often delayed in diagnosis due to their atypical clinical characteristics. Here, we describe a case of P-NET in the pancreatic tail. The tumor had metastasized to the liver and secreted gastrin and ACTH. A 60-year-old female patient was diagnosed with gastrinoma in the pancreatic tail with liver metastases in 2015. After 3 months, the patient presented refractory hypokalemia and thyroid dysfunction. The final diagnosis was P-NET with...
Source: Endocrine Journal - October 11, 2021 Category: Endocrinology Authors: Mao Zheng Li Chen Xiaomin Nie Dong Wang Jie Zhu Wei Wang An Ren Shandong Ye Source Type: research